Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation-Reference-Cited by-同舟云学术

Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation

Published:2011-06-13 Issue:6 Volume:6 Page:e20571
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Fernø Johan,Varela Luis,Skrede Silje,Vázquez María Jesús,Nogueiras Rubén,Diéguez Carlos,Vidal-Puig Antonio,Steen Vidar M.,López Miguel

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference53 articles.

1. Antipsychotic-induced weight gain: a comprehensive research synthesis.;DB Allison;Am J Psychiatry,1999

2. Consensus development conference on antipsychotic drugs and obesity and diabetes.;J Clin Psychiatry,2004

3. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states.;CW Colton;Prev Chronic Dis,2006

4. Obesity as a risk factor for antipsychotic noncompliance.;PJ Weiden;Schizophr Res,2004

5. Adiposity and eating behaviors in patients under second generation antipsychotics.;M Blouin;Obesity (Silver Spring),2008

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined sulforaphane and β-sitosterol mitigate olanzapine-induced metabolic disorders in rats: Insights on FOXO, PI3K/AKT, JAK/STAT3, and MAPK signaling pathways;International Immunopharmacology;2024-10

2. Aprepitant boasted a protective effect against olanzapine-induced metabolic syndrome and its subsequent hepatic, renal, and ovarian dysfunction; Role of IGF1/p-AKT/FOXO1 and NFκB/IL-1β/TNF-α signaling pathways in female Wistar albino rats;Biochemical Pharmacology;2024-03

3. Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders;International Clinical Psychopharmacology;2024-02-13

4. Olanzapine, risperidone and ziprasidone differently affect lysosomal function and autophagy, reflecting their different metabolic risk in patients;Translational Psychiatry;2024-01-08

5. Metabolic effects of atypical antipsychotics: Molecular targets;Journal of Neuroendocrinology;2023-10-22